Updated: After long slog, AstraZeneca finally gets CTLA-4 drug over finish line
It took years of sorting through failed trials to find the right dosing regimen, but AstraZeneca has finally landed an approval for its CTLA-4 inhibitor.
Imjudo — better known as tremelimumab, or treme — joins Bristol Myers Squibb’s Yervoy as the only FDA-approved CTLA-4 drug. The initial OK covers its use in unresectable hepatocellular carcinoma, the most common type of liver cancer.
AstraZeneca EVP of Oncology Dave Fredrickson told Endpoints News that the cost of the new Imjudo-Imfinzi regimen will be published in a few days, but that it will be “comparable” to other approved combination treatments in the liver cancer space.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters